the aid library

LIST OPTIONS

Filter

6724

How to support survivors of gender-based violence when a GBV actor is not available in your area

Inter-Agency Standing Committee (2023) CC

KEY MESSAGES Always talk to a GBV specialist first to understand what GBV services are available in your area. Some services may take the form of hotlines, a mobile app or other remote support. Be aware of any other available services in your area. Identify services provided by humanitarian pa...rtners such as health, psychosocial support, shelter and non-food items. Consider services provided by communities such as mosques/ churches, women’s groups and Disability Service Organizations. Remember your role. Provide a listening ear, free of judgment. Provide accurate, up-to-date information on available services. Let the survivor make their own choices. Know what you can and cannot manage. Even without a GBV actor in your area, there may be other partners, such as a child protection or mental health specialist, who can support survivors that require additional attention and support. Ask the survivor for permission before connecting them to anyone else. Do not force the survivor if s/he says no. Do not proactively identify or seek out GBV survivors. Be available in case someone asks for support. Remember your mandate. All humanitarian practitioners are mandated to provide non-judgmental and non-discriminatory support to people in need regardless of: gender, sexual orientation, gender identity, marital status, disability status, age, ethnicity/tribe/race/religion, who perpetrated/committed violence, and the situation in which violence was committed. Use a survivor-centered approach by practicing: Respect: all actions you take are guided by respect for the survivor’s choices, wishes, rights and dignity. Safety: the safety of the survivor is the number one priority. Confidentiality: people have the right to choose to whom they will or will not tell their story. Maintaining confidentiality means not sharing any information to anyone. Non-discrimination: providing equal and fair treatment to anyone in need of support. If health services exist, always provide information on what is available. Share what you know, and most importantly explain what you do not. Let the survivor decide if s/he wants to access them. Receiving quality medical care within 72 hours can prevent transmission of sexually transmitted infections (STIs), and within 120 hours can prevent unwanted pregnancy. Provide the opportunity for people with disabilities to communicate to you without the presence of their caregiver, if wished and does not endanger or create tension in that relationship. If a man or boy is raped it does not mean he is gay or bisexual. Gender-based violence is based on power, not someone’s sexuality. Sexual and gender minorities are often at increased risk of harm and violence due to their sexual orientation and/or gender identity. Actively listen and seek to support all survivors. Anyone can commit an act of gender-based violence including a spouse, intimate partner, family member, caregiver, in-law, stranger, parent or someone who is exchanging money or goods for a sexual act. Anyone can be a survivor of gender-based violence – this includes, but isn’t limited to, people who are married, elderly individuals or people who engage in sex work. Protect the identity and safety of a survivor. Do not write down, take pictures or verbally share any personal/identifying information about a survivor or their experience, including with your supervisor. Put phones and computers away to avoid concern that a survivor’s voice is being recorded. Personal/identifying information includes the survivor’s name, perpetrator(s) name, date of birth, registration number, home address, work address, location where their children go to school, the exact time and place the incident took place etc. Share general, non-identifying information To your team or sector partners in an effort to make your program safer. To your support network when seeking self-care and encouragement. more

Download (229)

View PDF (348)

The Burden of Pediatric Asthma

Ferrante, G.; La Grutta, S. Frontiers in Pediatrics (2018) CC

Asthma is the most common chronic disease in children, imposing a consistent burden on health system. In recent years, prevalence of asthma symptoms became globally increased in children and adolescents, particularly in Low-Middle Income Countries (LMICs). Host (genetics, atopy) and environmental fa... more

Download (255)

View PDF (431)

Pediatric oncology nursing practice in Latin America and the Caribbean

Pan American Health Organisation PAHO (2024) C_WHO

One of the main aims of the WHO Global Initiative for Childhood Cancer and the CureAll Americas framework is to strengthen centers of excellence and promote the training of the health workforce, especially pediatric oncology nurses, specialized in nursing care for children and adolescents with cance... more

ERS/EAACI statement on adherence to international adult asthma guidelines

Mathioudakis, A.G.; Tsilochristou, O.; Adcock, I. M.; et al. (2021) CC2

In the European Union, over 20 million people suffer from asthma. During the 1990s there was a rapid decrease in asthma mortality, probably related to the increased use of inhaled corticosteroids (ICS). However, during the last decade, asthma mortality rates have plateaued, and a consistently high p... more

External Link (711)

European Respiratory Society guidelines for the diagnosis of asthma in adults

Renaud, L.; Imran, S.; Inigo, O., et al. European Respiratory Journal (2022) CC

Although asthma is very common, affecting 5–10% of the population, the diagnosis of asthma in adults remains a challenge in the real world, which results in both over- and under-diagnosis. A taskforce was set up by the European Respiratory Society to systematically review the literature on the dia... more

Download (278)

View PDF (550)

Updates to section 6.2.5 Antituberculosis medicines of the 2021 WHO Model List of Essential Medicines

World Health Organization WHO (2022) C_WHO

Download (882)

View PDF (1739)

Medicines Catalog August 2018

Global Drug Facility World Health Organization WHO, Stop TB (2018) C_WHO

The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months and moxifloxacin as the fluoroquinolone.

External Link

Availability, Affordability, Access, and Pricing of Anti-cancer Medicines in Low- and Middle-Income Countries: A Systematic Review of Literature

Ocran Mattila, P.; R. Ahmad, S.Shahzad Hasan, et al. (2021) C2

Front. Public Health, 30 April 2021 | https://doi.org/10.3389/fpubh.2021.628744

Download (1778)

View PDF (3367)

WHO Model Formulary
recommended

World Health Organization WHO (2008) C_WHO

For each medicine the Formulary provides information on use, dosage, adverse effects, contraindications and warnings, supplemented by guidance on selecting the right medicine for a range of conditions

Download (15693)

View PDF (1438)

Neuraxial Blockade and Anticoagulation - Handout

International federation of nurse anesthetics (2014)

Handout presentations in PDF for illustrating lectures Accessed May 2014

Download (814)

View PDF (1544)

Integrating palliative care and symptom relief into paediatrics: a WHO guide for health-care planners, implementers and managers

World Health Organization WHO (2018) C_WHO

People younger than 20 years comprise 35% of the global population and 40% of the global population of least-developed nations. The number of children - neonates, infants, children, and adolescents up to 19 years of age - who need pediatric palliative care (PPC) each year may be as high as 21 millio... more

Download (766)

View PDF (1612)

Integrating palliative care and symptom relief into primary health care : WHO guide for planners, implementers and managers

World Health Organization WHO (2018) C_WHO

Inequality of access to palliative care and symptom relief is one of the greatest disparities in global health care (1). Currently, there is avoidable suffering on a massive scale due to lack of access to palliative care and symptom relief in low- and middle-income countries (LMICs) (1). Yet basic p... more

Download (1545)

View PDF (4141)

Clinical care for survivors of Ebola virus disease
recommended

World Health Organization (WHO) (2016) C_WHO

Interim Guidance.
A number of medical problems have been reported in survivors, including mental health issues. Ebola virus may persist in some body fluids, including semen. Ebola survivors need comprehensive support for the medical and psychosocial challenges they face and also to minimize the ... more

Download (221)

View PDF (403)

Considerations on the Use of Antivirals, Monoclonal Antibodies, and Other Interventions for the Management of COVID-19 Patients in Latin America and the Caribbean

World Health Organization WHO; PAHO; et al. (2022) CC

May 9, 2022.Since the onset of the COVID-19 pandemic, a large number of clinical trials have been planned and developed to assess the effectiveness and safety of various interventions that could prevent hospitalizations and progression to severe disease in people infected with SARS-CoV-2. Currently,... more

Download (325)

View PDF (339)

Child-friendly formulations for drug-resistant tuberculosis

Stop TB Partnership World Health Organization WHO (2022) CC

Technical information note. Ensuring an uninterrupted supply of quality-assured, affordable anti-TB drugs and diagnostics to the world

Download (992)

View PDF (1581)

Philippines: 2014 HSP Consensus Statement on the Management of Chronic Hepatitis B
recommended

Hepatology Society of the Philippines (2014) C1

Download (276)

View PDF (453)

Therapeutics for Ebola virus disease
recommended

World Health Organization WHO (2022) C_WHO

The WHO Ebola Virus Disease (EVD) Clinical management: living guidance contains the Organization’s most up-to-date recommendations for the clinical management of people with EVD. Providing guidance that is comprehensive and holistic for the optimal care of patients with EVD throughout their il... more

Download (461)

View PDF (581)

HEARTS. Accès aux médicaments essentiels et aux technologies de santé de base

Organisation Mondiale de la Santé OMS, et al. (2018) C_WHO

Guide technique pour la prise en charge des maladies cardiovasculaires dans le cadre des soins de santé primaires

Download (260)

View PDF (377)

WHO Living guideline: Drugs to prevent COVID-19
recommended

World Health Organization WHO (2021) C_WHO

Interim guidance 2 march 2021 Current use of drugs to prevent COVID-19 is variable, reflecting large-scale uncertainty. Numerous randomized trials of many different drugs are underway to inform practice. This first version of the Drugs to prevent COVID-19: A WHO living guideline contains new inform... more

Download (308)

View PDF (403)

Information sheet: Management of tuberculosis in children and adolescents

World Health Organization WHO (2022) C_WHO

WHO Model Formulary recommended

Clinical care for survivors of Ebola virus disease recommended

Philippines: 2014 HSP Consensus Statement on the Management of Chronic Hepatitis B recommended

Therapeutics for Ebola virus disease recommended

WHO Living guideline: Drugs to prevent COVID-19 recommended

WHO Model Formulary
recommended

Clinical care for survivors of Ebola virus disease
recommended

Philippines: 2014 HSP Consensus Statement on the Management of Chronic Hepatitis B
recommended

Therapeutics for Ebola virus disease
recommended

WHO Living guideline: Drugs to prevent COVID-19
recommended